UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000046031
Receipt number R000052542
Scientific Title Association of circulating tumor cell gene mutations and peripheral blood lymphocyte telomere length with the frequency and severity of immune-related pneumonitis in lung cancer patients receiving cancer immunotherapy
Date of disclosure of the study information 2021/12/01
Last modified on 2022/03/21 11:19:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Association of circulating tumor cell gene mutations and peripheral blood lymphocyte telomere length with the frequency and severity of immune-related pneumonitis in lung cancer patients receiving cancer immunotherapy

Acronym

Association of circulating tumor cell gene mutations and peripheral blood lymphocyte telomere length with the frequency and severity of immune-related pneumonitis in lung cancer patients receiving cancer immunotherapy

Scientific Title

Association of circulating tumor cell gene mutations and peripheral blood lymphocyte telomere length with the frequency and severity of immune-related pneumonitis in lung cancer patients receiving cancer immunotherapy

Scientific Title:Acronym

Association of circulating tumor cell gene mutations and peripheral blood lymphocyte telomere length with the frequency and severity of immune-related pneumonitis in lung cancer patients receiving cancer immunotherapy

Region

Japan


Condition

Condition

Lung cancer

Classification by specialty

Medicine in general Pneumology Hematology and clinical oncology
Adult

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To investigate the association between driver gene mutations of circulating tumor DNA (ctDNA) in blood and telomere length of peripheral blood lymphocytes in lung cancer patients and the frequency and severity of immune-related pneumonitis during cancer immunotherapy.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The frequency and severity of immune-related pneumonitis during cancer immunotherapy.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The patient who has been histopathologically diagnosed with lung cancer.

The patient who are planning to undergo cancer immunotherapy.

Key exclusion criteria

Those who do not consent to the research.

Target sample size

70


Research contact person

Name of lead principal investigator

1st name Kohei
Middle name
Last name Fujita

Organization

National Hospital Organization Kyoto Medical Center

Division name

Respiratory Medicine

Zip code

612-8555

Address

1-1, Fukakusa-Mukaihata, Fushimi-Ku, Kyoto, Japan

TEL

0756419161

Email

kfujita.acd@gmail.com


Public contact

Name of contact person

1st name Kohei
Middle name
Last name Fujita

Organization

NHO Kyoto Medical Center

Division name

Respiratory Medicine

Zip code

612-8555

Address

1-1, Fukakusa-Mukaihata, Fushimi-Ku, Kyoto, Japan

TEL

0756419161

Homepage URL


Email

kfujita.acd@gmail.com


Sponsor or person

Institute

NHO Kyoto Medical Center

Institute

Department

Personal name



Funding Source

Organization

NHO Kyoto Medical Center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

MiRTel Co.,Ltd.

Name of secondary funder(s)



IRB Contact (For public release)

Organization

NHO Kyoto Medical Center

Address

1-1, Fukakusa-Mukaihata, Fushimi-Ku, Kyoto, Japan

Tel

0756419161

Email

yamaji.hirofumi.bg@mail.hosp.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立病院機構京都医療センター


Other administrative information

Date of disclosure of the study information

2021 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2021 Year 11 Month 15 Day

Date of IRB

2021 Year 11 Month 15 Day

Anticipated trial start date

2021 Year 12 Month 01 Day

Last follow-up date

2024 Year 12 Month 01 Day

Date of closure to data entry

2025 Year 12 Month 01 Day

Date trial data considered complete

2025 Year 12 Month 01 Day

Date analysis concluded

2025 Year 12 Month 31 Day


Other

Other related information

To investigate the association between driver gene mutations of circulating tumor DNA (ctDNA) in blood and telomere length of peripheral blood lymphocytes in lung cancer patients and the frequency and severity of immune-related interstitial pneumonia during cancer immunotherapy.


Management information

Registered date

2021 Year 11 Month 10 Day

Last modified on

2022 Year 03 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052542


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name